RusBioPharm

Rusbiopharm is a prominent Russian pharmaceutical company dedicated to the development and production of complex generic and biosimilar medications. Headquartered in Moscow with a state-of-the-art manufacturing site in the Dubna Special Economic Zone, the company focuses on critical therapeutic areas including endocrinology, nephrology, and oncology. Rusbiopharm is a key participant in Russia's import substitution initiatives, providing high-quality alternatives for essential drugs such as insulin analogues and GLP-1 receptor agonists. Their business model integrates R&D with full-cycle manufacturing capabilities to ensure the availability of affordable treatments for chronic conditions like diabetes and osteoporosis. The company has successfully launched several high-tech products, including biosimilars of liraglutide and semaglutide, strengthening its position in the metabolic disease market.